CDT Equity (NASDAQ:CDT – Get Free Report) and Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.
Institutional & Insider Ownership
3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 10.8% of CDT Equity shares are owned by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares CDT Equity and Xenetic Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CDT Equity | N/A | -145.29% | -103.25% |
| Xenetic Biosciences | -70.03% | -39.28% | -33.47% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CDT Equity | 1 | 0 | 0 | 0 | 1.00 |
| Xenetic Biosciences | 1 | 0 | 0 | 0 | 1.00 |
Risk and Volatility
CDT Equity has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.
Earnings and Valuation
This table compares CDT Equity and Xenetic Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CDT Equity | N/A | N/A | -$39.22 million | ($14,265.60) | -0.00 |
| Xenetic Biosciences | $2.98 million | 2.27 | -$2.68 million | ($1.20) | -2.47 |
Xenetic Biosciences has higher revenue and earnings than CDT Equity. Xenetic Biosciences is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.
Summary
Xenetic Biosciences beats CDT Equity on 7 of the 10 factors compared between the two stocks.
About CDT Equity
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Receive News & Ratings for CDT Equity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CDT Equity and related companies with MarketBeat.com's FREE daily email newsletter.
